Vaxcyte (PCVX) $632.5M Stock Offering Follows Bullish Cantor Fitzgerald Rating
Vaxcyte Inc. (NASDAQ: PCVX) completed a public offering of 12.65 million shares at $50 each, raising $632.5 million. This offering follows Cantor Fitzgerald's reaffirmed Overweight rating on January 23, citing the company's progressing clinical pipeline. Vaxcyte focuses on developing vaccines for infectious diseases using cell-free protein synthesis technology, with key trial readouts expected in Q4 2026 and H1 2027.
Vaxcyte shows market leadership with jump to 85 RS rating
Vaxcyte (PCVX) has seen its IBD SmartSelect Composite Rating rise to 96, placing it among the top 4% of all stocks. Its Relative Strength (RS) Rating has improved to 85, indicating strong market performance. The company's earnings per share (EPS) rating is 80, contributing to its overall strong financial health perception.
Vaxcyte Inc. (PCVX) Confident of Topline Data in Pneumococcal Vaccine Trials
Vaxcyte Inc. (PCVX) has announced confidence in its upcoming topline data for its VAX-31 pneumococcal conjugate vaccine trials. The company recently dosed the first participants in its OPUS-3 Phase 3 trial and expects results from both OPUS-2 and OPUS-3 trials in the first half of 2027. Vaxcyte also completed a $632.5 million public offering, strengthening its financial position for vaccine development.
A Look At Vaxcyte (PCVX) Valuation After OPUS-3 Phase 3 Dosing Milestone
Vaxcyte (PCVX) has started dosing in its OPUS-3 Phase 3 trial, boosting its stock price which has seen significant short-term gains despite a long-term decline. Simply Wall St's DCF model suggests a fair value of $99.36, indicating potential undervaluation compared to its current price of $56.17, although the company is still reporting losses and generating no revenue. Investors should weigh the projected upside against the risks associated with a clinical-stage biotech and its reliance on future commercialization.
Vaxcyte Inc. (PCVX) Confident of Topline Data in Pneumococcal Vaccine Trials
Vaxcyte Inc. (PCVX) has initiated its OPUS-3 Phase 3 trial for the VAX-31 pneumococcal conjugate vaccine, targeting adults previously vaccinated against pneumococcal disease. The company expects topline data from its OPUS-2 and OPUS-3 trials in the first half of 2027 and recently secured $632.5 million through a public offering to fund its vaccine development. VAX-31 has already received Breakthrough Therapy designation from the FDA.
Vaxcyte (PCVX) $632.5M Stock Offering Follows Bullish Cantor Fitzgerald Rating
Vaxcyte Inc. recently closed a public offering, raising $632.5 million through the sale of 12.65 million shares at $50 each. This offering followed a reiterated "Overweight" rating from Cantor Fitzgerald, which highlighted the promising progress of the company's clinical pipeline, including expected Phase 3 trial readouts in 2026 and 2027. Vaxcyte specializes in developing vaccines for infectious diseases using cell-free protein synthesis technology.
Vaxcyte (PCVX) $632.5M Stock Offering Follows Bullish Cantor Fitzgerald Rating
Vaxcyte Inc. (PCVX) recently closed a public offering of 12.65 million shares at $50 each, raising $632.5 million. This stock offering follows a reaffirmed "Overweight" rating from Cantor Fitzgerald, which noted the company's clinical pipeline for infectious disease vaccines is progressing on schedule. Key trial readouts are anticipated in late 2026 and early 2027.
Impressive Clinical Pipeline Leads to Bullish Sentiment for Vaxcyte (PCVX)
Vaxcyte (PCVX) is experiencing bullish sentiment due to its promising clinical pipeline, particularly for its pneumococcal vaccine. Cantor Fitzgerald maintained an "Overweight" rating, citing progress in Phase 3 trials, while Needham analyst Joseph Stringer raised his price target to $110, highlighting the strong Phase 2 data and potential for a best-in-class vaccine. The company is actively conducting multiple Phase 3 studies with results anticipated in late 2026 and early 2027.
Impressive Clinical Pipeline Leads to Bullish Sentiment for Vaxcyte (PCVX)
Vaxcyte (PCVX) is experiencing bullish sentiment due to its impressive clinical pipeline, particularly for its next-generation pneumococcal vaccine, VAX-31. Cantor Fitzgerald maintained an Overweight rating, anticipating Phase 3 OPUS-1 results in Q4 2026, while Needham raised its price target to $110, citing strong Phase 2 data and potential best-in-class status. The company is actively progressing with its OPUS-1, OPUS-2, and OPUS-3 trials, with results expected in 2027.
Impressive Clinical Pipeline Leads to Bullish Sentiment for Vaxcyte (PCVX)
Vaxcyte Incorporated (PCVX) is experiencing bullish sentiment due to its impressive clinical pipeline, particularly for its pneumococcal vaccine. Analysts from Cantor Fitzgerald and Needham have maintained or raised ratings and price targets, citing strong Phase 2 data and anticipated Phase 3 readouts in 2026 and 2027. The company is developing next-generation vaccines using innovative synthetic methods and advanced chemistry.
Impressive Clinical Pipeline Leads to Bullish Sentiment for Vaxcyte (PCVX)
Vaxcyte Incorporated (NASDAQ: PCVX) is receiving bullish sentiment from analysts due to its impressive clinical pipeline. Cantor Fitzgerald maintained an Overweight rating, noting progress in its OPUS trials. Needham analyst Joseph Stringer raised the price target to $110 with a Buy rating, highlighting strong Phase 2 data for VAX-31 and its potential as a best-in-class pneumococcal vaccine.
Precision Trading with Vaxcyte Inc. (PCVX) Risk Zones
This article from Stock Traders Daily discusses Vaxcyte Inc. (PCVX) and presents a "Precision Trading" analysis. It highlights near-term weak sentiment, tests resistance, and offers an exceptional risk-reward short setup. The analysis provides institutional trading strategies for different risk profiles, including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis.
Vaxcyte Spotlights VAX-31 Phase 3 Launch, Eyes Adult BLA by End of Next Year at Biotech Summit
Vaxcyte highlighted the launch of its Phase 3 adult program for VAX-31, a 31-valent pneumococcal conjugate vaccine, at a recent biotech summit. The company aims for a Biologics License Application (BLA) submission for adults by the end of next year, with approval and launch targeted for 2028. Vaxcyte's proprietary conjugation approach is designed to overcome the serotype coverage limitations of existing vaccines.
Vaxcyte Spotlights VAX-31 Phase 3 Launch, Eyes Adult BLA by End of Next Year at Biotech Summit
Vaxcyte has highlighted the launch of its VAX-31 Phase 3 adult program, aiming for a Biologics License Application (BLA) submission by the end of next year. The company's proprietary conjugation approach allows for a 31-valent pneumococcal conjugate vaccine (PCV), which it claims surpasses the typical 20-21 serotype ceiling with broader coverage and improved immune responses. Vaxcyte also announced it has over $3 billion in pro forma funding for multiple planned Phase 3 studies and international commercialization strategies.
Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial
Vaxcyte, Inc. has dosed the first participants in its OPUS-3 Phase 3 trial for VAX-31, a 31-valent pneumococcal conjugate vaccine candidate. This trial evaluates VAX-31 in adults previously vaccinated with lower-valency pneumococcal vaccines, assessing its safety, tolerability, and immunogenicity to potentially broaden serotype coverage. Vaxcyte anticipates reporting topline data from its OPUS-3 and OPUS-2 trials in the first half of 2027, with OPUS-1 data expected in the fourth quarter of 2026, aiming for a Biologics License Application (BLA) submission afterward.
Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026
Vaxcyte, Inc. announced that it will report its financial results for the fourth quarter and full year 2025 and provide a business update on February 24, 2026, after market close. The company will host a conference call and webcast to discuss these results and updates. Vaxcyte is a clinical-stage vaccine innovation company developing several vaccine candidates, including VAX-31 and VAX-24 for pneumococcal disease, using its XpressCF® cell-free protein synthesis platform.
Vaxcyte (PCVX) Initiates Phase 3 Trial for VAX-31 Vaccine in Adu
Vaxcyte (PCVX) has commenced its OPUS-3 Phase 3 trial for the VAX-31 vaccine, a 31-valent pneumococcal conjugate vaccine designed for adults. Despite reporting no revenue and negative earnings, the company exhibits strong liquidity and minimal leverage. High institutional ownership and a moderate buy recommendation reflect cautious optimism, though risks include high volatility and significant insider selling.
Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial
Vaxcyte has announced the dosing of the first participants in its OPUS-3 Phase 3 trial for VAX-31, a 31-valent pneumococcal conjugate vaccine candidate. This trial evaluates VAX-31 in adults previously vaccinated with lower-valency pneumococcal vaccines, aiming to boost immune responses and broaden serotype coverage. The company expects to report topline data from OPUS-3 and OPUS-2 trials in the first half of 2027, with the comprehensive Phase 3 program supporting a planned Biologics License Application submission.
VAX-31 pneumonia shot enters Phase 3 for previously vaccinated adults
Vaxcyte (Nasdaq: PCVX) has initiated the OPUS-3 Phase 3 trial for its 31-valent pneumococcal conjugate vaccine, VAX-31, in adults previously vaccinated with lower-valency pneumococcal vaccines. This trial is part of a larger Phase 3 program involving approximately 6,000 participants, aiming to support a Biologics License Application (BLA) submission for VAX-31, which is designed to cover about 95% of invasive pneumococcal disease and 88% of pneumococcal pneumonia in U.S. adults aged 50 and older. Topline data from OPUS-1 are expected in Q4 2026, while OPUS-2 and OPUS-3 results are anticipated in H1 2027.
Vaxcyte, Inc. (NASDAQ:PCVX) Given Consensus Rating of "Moderate Buy" by Analysts
Analysts have given Vaxcyte, Inc. (NASDAQ:PCVX) a consensus "Moderate Buy" rating, with an average 12-month price target of $93.83. This comes despite recent insider sales from two executives, Harpreet S. Dhaliwal and Elvia Cowan, who reduced their stakes in the company. Vaxcyte is a clinical-stage biotech company focused on developing preventive vaccines for serious bacterial diseases, with its lead candidate being VAX-24, a 24-valent pneumococcal conjugate vaccine.
Vaxcyte to Report Fourth Quarter and Full Year 2025
Vaxcyte, Inc. will report its financial results for the fourth quarter and full year 2025 and provide a business update on February 24, 2026, after market close. Company management will host a conference call and webcast to discuss these results. Vaxcyte is a clinical-stage vaccine company developing several pneumococcal conjugate vaccine (PCV) candidates, including VAX-31 and VAX-24, and other vaccine candidates for Group A Strep and Shigella.
Vaxcyte, Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update on February 24, 2026
Vaxcyte, Inc. (Nasdaq: PCVX) announced it will report its financial results for the fourth quarter and full year 2025 on February 24, 2026, after market close, followed by a conference call and webcast. The company focuses on developing innovative vaccines for bacterial diseases, including advanced candidates like VAX-31 and VAX-24 for invasive pneumococcal disease, utilizing its proprietary XpressCF® platform. Insider trading data shows sales by executives, while institutional investors show mixed activity, and analysts predominantly rate the stock as "Buy."
How Investors May Respond To Vaxcyte (PCVX) Raising $550 Million To Fund Pneumococcal Vaccine Pipeline
Vaxcyte recently raised $550 million through a follow-on equity offering to advance its VAX-24 and VAX-31 pneumococcal vaccine candidates. While this move strengthens the company's financial position and reduces near-term financing uncertainty for key 2026 data readouts, it also contributes to share dilution and highlights the remaining clinical, regulatory, and commercialization risks for the pre-revenue biotech. Investors must weigh the potential for a successful pneumococcal franchise against the significant risks and ongoing unprofitability of the company.
How Investors May Respond To Vaxcyte (PCVX) Raising $550 Million To Fund Pneumococcal Vaccine Pipeline
Vaxcyte (PCVX) recently raised $550 million through an equity offering to advance its VAX-24 and VAX-31 pneumococcal vaccine candidates through clinical development. While this strengthens the balance sheet and reduces near-term financing uncertainty, it also adds to an already dilutive capital structure and follows a weak 1-year share return. The article discusses how investors might view this capital raise given the company's lack of revenue and significant losses, emphasizing the ongoing clinical, regulatory, and commercialization risks despite the improved financial runway.
Vaxcyte to Present at the Guggenheim Emerging Outlook: Biotech Summit
Vaxcyte, Inc. announced that its management will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit on February 12, 2026. The clinical-stage vaccine company is focused on developing high-fidelity vaccines for bacterial diseases, with a pipeline including advanced pneumococcal conjugate vaccine candidates and other prophylactic vaccines. A live webcast of the chat will be available on the company's investor relations website, with a replay accessible for about 30 days.
Vaccine developer Vaxcyte joins Guggenheim biotech summit webcast
Vaxcyte (Nasdaq: PCVX) announced its management will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit in New York on February 12, 2026, at 1:30 p.m. ET. A live webcast will be available via the company's investor site, with a replay accessible for approximately 30 days. This event follows recent significant capital raises and advancements in its VAX-31 vaccine development programs.
Commit To Buy Vaxcyte At $45, Earn 19.3% Annualized Using Options
The article discusses an options strategy for investors interested in Vaxcyte Inc (PCVX) stock, suggesting selling a January 2027 put contract at the $45 strike price. This strategy allows investors to collect a premium, representing a 19.3% annualized return, while committing to buy the stock at $45 if the option is exercised. The approach is recommended for those who are hesitant about the current market price of $55.42/share but are comfortable owning the stock at a lower price.
Vaxcyte to Present at the Guggenheim Emerging Outlook: Biotech Summit
Vaxcyte, Inc., a clinical-stage vaccine innovation company, announced its management will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit on February 12, 2026. The company will discuss its advanced vaccine pipeline, including its pneumococcal conjugate vaccine (PCV) candidates VAX-31 and VAX-24, and its proprietary XpressCF® cell-free protein synthesis platform. Vaxcyte aims to develop high-fidelity vaccines against bacterial diseases, with other candidates targeting Group A Strep and Shigella.
Technical Reactions to PCVX Trends in Macro Strategies
The article provides a technical analysis of Vaxcyte Inc. (NASDAQ: PCVX), highlighting a strong near and mid-term sentiment but a weak long-term outlook. It details specific trading strategies, including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis for support and resistance levels. The analysis suggests a significant short setup opportunity with an exceptional risk-reward ratio.
Vaxcyte raises $632.5M by selling 12.7M shares at $50 each
Vaxcyte (Nasdaq: PCVX) has successfully closed a public offering, raising $632.5 million through the sale of 12,650,000 shares at $50.00 each. This amount includes the full exercise of the underwriters' option to purchase additional shares. The company plans to use these proceeds to support its vaccine pipeline, though existing shareholders will experience dilution.
Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Vaxcyte, Inc. (Nasdaq: PCVX) has announced the closing of its underwritten public offering, raising $632.5 million in gross proceeds. The offering included the full exercise of the underwriters' option to purchase an additional 1,650,000 shares of common stock at $50.00 per share. This financial move supports Vaxcyte's mission as a clinical-stage vaccine innovation company, advancing its various vaccine candidates, including pneumococcal conjugate vaccines and other prophylactic treatments.
Vaxcyte closes $632.5 million public offering of common stock
Vaxcyte, Inc. announced the closing of its public offering, raising $632.5 million in gross proceeds by selling 12,650,000 shares of common stock at $50.00 each. The offering capitalized on the full exercise of underwriters' option for additional shares, reflecting a 14.8% premium over the current share price. The company, which is developing several vaccine candidates including VAX-31 and VAX-24, has received positive analytical outlooks from firms like Cantor Fitzgerald, Evercore ISI, and Jefferies.
Vaxcyte Announces Closing of $632.5 Million Public Offering
Vaxcyte, Inc. has announced the closing of its underwritten public offering, raising $632.5 million. This figure includes the full exercise of the underwriters' option to purchase additional shares. The company, a clinical-stage vaccine innovator, focuses on developing high-fidelity vaccines to combat bacterial diseases.
Vaxcyte, Inc. Completes $632.5 Million Public Offering of Common Stock
Vaxcyte, Inc. has successfully closed an underwritten public offering, raising $632.5 million from the sale of 12,650,000 shares of common stock at $50.00 per share, including the full exercise of the underwriters' option. The funds are earmarked for advancing its vaccine development programs, including lead candidates VAX-31 and VAX-24 for pneumococcal disease. The offering was managed by several financial institutions, with BofA Securities and Jefferies acting as joint book-running managers.
Vaxcyte, Inc. Completes $632.5 Million Public Offering of Common Stock
Vaxcyte, Inc. announced the successful completion of its underwritten public offering, raising $632.5 million through the sale of 12,650,000 shares of common stock at $50.00 per share, including the full exercise of the underwriters' option. The capital raised will support the company's vaccine development programs, including clinical-stage candidates VAX-31 and VAX-24 for pneumococcal disease. The offering saw participation from major financial institutions and reflects strong interest in Vaxcyte's innovative XpressCF® platform for complex vaccine development.
Vaxcyte Announces Closing of $632.5 Million Public Offering
Vaxcyte, Inc. announced the closing of its underwritten public offering, raising $632.5 million in aggregate gross proceeds. The offering included the full exercise of the underwriters’ option to purchase additional shares, totaling 12,650,000 shares of common stock at $50.00 per share. BofA Securities, Jefferies, Leerink Partners, Evercore ISI, and Guggenheim Securities acted as joint book-running managers for this offering.
Guggenheim Reiterates Buy Rating on Vaxcyte (PCVX) at $116 Targe
Guggenheim has reiterated its "Buy" rating for Vaxcyte (PCVX), maintaining a price target of $116, reflecting continued confidence in the company's prospects. This decision aligns with the average analyst target price of $100.22, suggesting an 81.79% upside from the current trading price. Vaxcyte is a clinical-stage vaccine company focused on developing high-fidelity vaccines for bacterial diseases.
Vaxcyte (NASDAQ:PCVX) Earns Buy Rating from Guggenheim
Guggenheim has reaffirmed a "Buy" rating for Vaxcyte (NASDAQ:PCVX) with a $116 price target, indicating a potential upside of over 110%. Despite a mixed financial performance, including missing EPS estimates, the clinical-stage vaccine maker maintains a "Moderate Buy" consensus rating from analysts. The article also highlights recent insider selling activity and significant institutional ownership in the company.
Vaxcyte (PCVX) Valuation Check After $550 Million Follow On Equity Offering
Vaxcyte (PCVX) recently completed a $550 million equity offering at $50 per share, with current shares trading at $53.57. Despite being a pre-revenue biotech firm, its Price-to-Book ratio of 2.4x is significantly lower than its peer average, suggesting it might be undervalued. A Discounted Cash Flow model also indicates undervaluation, with an estimated future cash flow value of $104.45 against its current trading price.
Latham & Watkins Advises on Vaxcyte’s US$550 Million Public Offering
Latham & Watkins LLP advised the underwriters in Vaxcyte, Inc.'s US$550 million public offering of common stock. Vaxcyte, a clinical-stage vaccine innovation company, is selling 11 million shares at US$50 per share, with an option for underwriters to purchase an additional 1.65 million shares. The Latham & Watkins team was led by Shayne Kennedy and Richard Kim, with support on regulatory, IP, and tax matters.
Vaxcyte prices $550 million public offering of common stock By Investing.com
Vaxcyte, Inc. has priced an underwritten public offering of 11 million shares of common stock at $50.00 per share, aiming to generate $550 million in gross proceeds. The offering is expected to close on February 2, 2026. The clinical-stage vaccine company maintains a strong financial position and is actively developing several vaccine candidates, including VAX-31 and VAX-24, utilizing its XpressCF platform.
Eikon aims high for NASDAQ listing: Public Equity Report
Eikon Therapeutics Inc. is preparing for a NASDAQ listing, aiming to raise $300 million through its IPO. The company, led by former Merck EVP Roger Perlmutter, plans to advance both in-licensed and internally developed candidates using its single-molecule tracking technology. This comes as two companies, including Eikon, propose terms for their IPOs, indicating potential new listings in the coming week.
Vaxcyte edges higher after upsized $550 mln equity raise
Vaxcyte (PCVX) saw its stock price increase following an announcement of an upsized equity raise. The company successfully completed a $550 million equity offering, which was larger than initially planned. This financial move appears to have been positively received by the market.
Vaccine maker looks to raise half a billion dollars to attack an $8 billion market
Vaxcyte plans to raise over $500 million to develop a pneumococcal vaccine, aiming to compete with pharmaceutical giants Pfizer and Merck in the $8 billion market. The company's CEO, Grant Pickering, is leading this initiative to challenge established players in the vaccine industry.
PCVX Increases Common Stock Offering to $550 Million
Vaxcyte, Inc. (PCVX) has announced an increase in its common stock offering from $500 million to $550 million, signaling strong investor confidence in the biotechnology company. Despite being a clinical-stage firm without current revenue, Vaxcyte maintains a robust balance sheet with high liquidity and low debt, supported by positive analyst recommendations and high institutional ownership. Investors are advised to consider the company's high volatility and sector-specific risks alongside its financial strengths.
Vaxcyte prices $550 million public offering of common stock By Investing.com
Vaxcyte, Inc. has priced an underwritten public offering of 11 million shares of common stock at $50.00 per share, aiming to raise $550 million in gross proceeds. The clinical-stage vaccine company, which has seen a significant return in its stock price, is developing several vaccine candidates, including a pneumococcal conjugate vaccine in Phase 3 trials. Analysts currently maintain a Strong Buy consensus for Vaxcyte, which is trading slightly above its Fair Value, and the company expects its next earnings report on March 2, 2026.
Vaxcyte sells 11M new shares in $550M stock offering at $50
Vaxcyte (Nasdaq: PCVX) announced the pricing of an underwritten public offering of 11 million common shares at $50.00 per share, aiming to raise $550 million before fees. The company has also granted underwriters a 30-day option to purchase an additional 1.65 million shares. The offering is anticipated to close on February 2, 2026, with the proceeds intended to fund its ongoing vaccine development and commercialization efforts.
Vaxcyte prices $550 million public offering of common stock
Vaxcyte, Inc. has announced the pricing of a $550 million public offering of 11 million shares of common stock at $50.00 per share, with the transaction expected to close on February 2, 2026. The company, a clinical-stage vaccine innovator, has a strong financial position, as indicated by a current ratio of 8.83, and is progressing with several vaccine candidates, including VAX-31 and VAX-24. Analysts maintain a "Strong Buy" consensus, and recent developments include the launch of a $500 million public offering and the initiation of its Phase 3 OPUS trial for the VAX-31 vaccine.
Vaxcyte Announces Pricing of $550 Million Public Offering
Vaxcyte, Inc. announced the pricing of an underwritten public offering of 11,000,000 shares of common stock at $50.00 per share, aiming to raise $550 million in gross proceeds. The company has also granted underwriters a 30-day option to purchase an additional 1,650,000 shares. The offering is expected to close on February 2, 2026.
Vaxcyte Announces Pricing of $550 Million Public Offering
Vaxcyte, Inc. announced the pricing of an underwritten public offering of 11,000,000 shares of common stock at $50.00 per share, aiming to raise $550 million in gross proceeds. The offering is expected to close on February 2, 2026, with underwriters having an option to purchase an additional 1,650,000 shares. The company, a clinical-stage vaccine innovator, focuses on developing high-fidelity vaccines for bacterial diseases, including several pneumococcal conjugate vaccine (PCV) candidates and other prophylactic vaccines.
